FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947518394> ?p ?o ?g. }

• W2947518394 abstract "ONC201 is a small molecule antagonist of DRD2, a G protein-coupled receptor overexpressed in several malignancies, that has prolonged antitumor efficacy and immunomodulatory properties in preclinical models. The first-in-human trial of ONC201 previously established a recommended phase II dose (RP2D) of 625 mg once every three weeks. Here, we report the results of a phase I study that evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of weekly ONC201.Patients ≥ 18 years old with an advanced solid tumor refractory to standard treatment were enrolled. Dose escalation proceeded with a 3 + 3 design from 375 mg to 625 mg of ONC201. One cycle, also the dose-limiting toxicity (DLT) window, was 21 days. The primary endpoint was to determine the RP2D of weekly ONC201, which was confirmed in an 11-patient dose expansion cohort.Twenty patients were enrolled: three at 375 mg and 17 at 625 mg of ONC201. The RP2D was defined as 625 mg with no DLT, treatment discontinuation, or dose modifications due to drug-related toxicity. PK profiles were consistent with every-three-week dosing and similar between the first and fourth dose. Serum prolactin and caspase-cleaved cytokeratin-18 induction were detected, along with intratumoral integrated stress response activation and infiltration of granzyme B+ Natural Killer cells. Induction of immune cytokines and effectors was higher in patients who received ONC201 once weekly versus once every three weeks. Stable disease of > 6 months was observed in several prostate and endometrial cancer patients.Weekly, oral ONC201 is well-tolerated and results in enhanced immunostimulatory activity that warrants further investigation.NCT02250781 (Oral ONC201 in Treating Patients With Advanced Solid Tumors), NCT02324621 (Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors)." @default.
• W2947518394 created "2019-06-07" @default.
• W2947518394 creator A5003655999 @default.
• W2947518394 creator A5005399890 @default.
• W2947518394 creator A5007849033 @default.
• W2947518394 creator A5008547275 @default.
• W2947518394 creator A5009161513 @default.
• W2947518394 creator A5012047866 @default.
• W2947518394 creator A5018135741 @default.
• W2947518394 creator A5020783161 @default.
• W2947518394 creator A5021784997 @default.
• W2947518394 creator A5028030572 @default.
• W2947518394 creator A5029537735 @default.
• W2947518394 creator A5036916387 @default.
• W2947518394 creator A5039236232 @default.
• W2947518394 creator A5041474007 @default.
• W2947518394 creator A5042839574 @default.
• W2947518394 creator A5045679809 @default.
• W2947518394 creator A5048331793 @default.
• W2947518394 creator A5053602981 @default.
• W2947518394 creator A5054371540 @default.
• W2947518394 creator A5055837818 @default.
• W2947518394 creator A5056800304 @default.
• W2947518394 creator A5063899863 @default.
• W2947518394 creator A5067646281 @default.
• W2947518394 creator A5069911447 @default.
• W2947518394 creator A5070131350 @default.
• W2947518394 creator A5071773606 @default.
• W2947518394 creator A5074542465 @default.
• W2947518394 creator A5075201353 @default.
• W2947518394 creator A5075350327 @default.
• W2947518394 creator A5081735541 @default.
• W2947518394 creator A5084798760 @default.
• W2947518394 creator A5087694927 @default.
• W2947518394 creator A5087730416 @default.
• W2947518394 creator A5089654215 @default.
• W2947518394 date "2019-05-22" @default.
• W2947518394 modified "2023-10-10" @default.
• W2947518394 title "Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration" @default.
• W2947518394 cites W1494874414 @default.
• W2947518394 cites W1516464304 @default.
• W2947518394 cites W1969845354 @default.
• W2947518394 cites W1981498420 @default.
• W2947518394 cites W2016670931 @default.
• W2947518394 cites W2044217732 @default.
• W2947518394 cites W2095381714 @default.
• W2947518394 cites W2121232930 @default.
• W2947518394 cites W2140580240 @default.
• W2947518394 cites W2162606162 @default.
• W2947518394 cites W2167331614 @default.
• W2947518394 cites W2278250712 @default.
• W2947518394 cites W2283948643 @default.
• W2947518394 cites W2514974106 @default.
• W2947518394 cites W2571225631 @default.
• W2947518394 cites W2600944061 @default.
• W2947518394 cites W2740326264 @default.
• W2947518394 cites W2742158642 @default.
• W2947518394 cites W2767037713 @default.
• W2947518394 cites W2790751347 @default.
• W2947518394 doi "https://doi.org/10.1186/s40425-019-0599-8" @default.
• W2947518394 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6532211" @default.
• W2947518394 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31118108" @default.
• W2947518394 hasPublicationYear "2019" @default.
• W2947518394 type Work @default.
• W2947518394 sameAs 2947518394 @default.
• W2947518394 citedByCount "41" @default.
• W2947518394 countsByYear W29475183942019 @default.
• W2947518394 countsByYear W29475183942020 @default.
• W2947518394 countsByYear W29475183942021 @default.
• W2947518394 countsByYear W29475183942022 @default.
• W2947518394 countsByYear W29475183942023 @default.
• W2947518394 crossrefType "journal-article" @default.
• W2947518394 hasAuthorship W2947518394A5003655999 @default.
• W2947518394 hasAuthorship W2947518394A5005399890 @default.
• W2947518394 hasAuthorship W2947518394A5007849033 @default.
• W2947518394 hasAuthorship W2947518394A5008547275 @default.
• W2947518394 hasAuthorship W2947518394A5009161513 @default.
• W2947518394 hasAuthorship W2947518394A5012047866 @default.
• W2947518394 hasAuthorship W2947518394A5018135741 @default.
• W2947518394 hasAuthorship W2947518394A5020783161 @default.
• W2947518394 hasAuthorship W2947518394A5021784997 @default.
• W2947518394 hasAuthorship W2947518394A5028030572 @default.
• W2947518394 hasAuthorship W2947518394A5029537735 @default.
• W2947518394 hasAuthorship W2947518394A5036916387 @default.
• W2947518394 hasAuthorship W2947518394A5039236232 @default.
• W2947518394 hasAuthorship W2947518394A5041474007 @default.
• W2947518394 hasAuthorship W2947518394A5042839574 @default.
• W2947518394 hasAuthorship W2947518394A5045679809 @default.
• W2947518394 hasAuthorship W2947518394A5048331793 @default.
• W2947518394 hasAuthorship W2947518394A5053602981 @default.
• W2947518394 hasAuthorship W2947518394A5054371540 @default.
• W2947518394 hasAuthorship W2947518394A5055837818 @default.
• W2947518394 hasAuthorship W2947518394A5056800304 @default.
• W2947518394 hasAuthorship W2947518394A5063899863 @default.
• W2947518394 hasAuthorship W2947518394A5067646281 @default.
• W2947518394 hasAuthorship W2947518394A5069911447 @default.
• W2947518394 hasAuthorship W2947518394A5070131350 @default.
• W2947518394 hasAuthorship W2947518394A5071773606 @default.
• W2947518394 hasAuthorship W2947518394A5074542465 @default.
• W2947518394 hasAuthorship W2947518394A5075201353 @default.

• next